Christopher Bettacchi

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2019 · 96 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +10

The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19

Deborah Wentworth, Andrew Phillips, Kathryn Shaw‐Saliba et al. · Annals of Internal Medicine · 2022 · 63 citations · Full text

Life Sciences, Immunology, Infectious Diseases +15

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

Graham Smith, W. Keith Henry, Daniel Podzamczer et al. · Open Forum Infectious Diseases · 2021 · 61 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial

Jean‐Michel Molina, Yazdan Yazdanpanah, Alejandro Afani Saud et al. · The Lancet HIV · 2021 · 44 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Chloe Orkin, Jean‐Michel Molina, Pedro Cahn et al. · The Lancet HIV · 2023 · 32 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15